INAB IN8bio: Company Short-Term Debts

Symbol and logo of brand IN8bio Inc (INAB)

The development of innovative methods for combating hematological tumors remains autonomous from economic cycles and seasonal fluctuations. Intellectual property security is ensured by US localization and international regulations. The market dynamics of IN8bio, Inc. (INAB) securities, with a metric of 0.00, reflect the specifics of the biotech sector: a lack of regular profits and a strict dependence on medical test results and the inflow of external investment.

INAB IN8bio Inc. Company Short-Term Loans and Borrowings (07/04/2022 - 10/30/2026)

IN8bio Inc - analytical breakdowns and key metrics (INAB)

- stock price and consensus target price:
Stock Price IN8bio|INAB - Consensus Target
- company stock capitalization data:
Market Capitalization IN8bio, Inc.|INAB - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share IN8bio|INAB - Accounting Value of Company|Market Cap to Net Assets Ratio in8bio.com|INAB - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital IN8bio, Inc.|INAB - Long-Term Debt to Equity|Short-Term Debt to Equity IN8bio, Inc.|INAB - Company Debts|Debt to Book Capitalization Ratio IN8bio, Inc.|INAB - Long-Term Debt|Company Short-Term Debt IN8bio|Quick Ratio in8bio.com
- earnings and multiples data:
INAB - Company Profit
Fundamental company valuation:INAB - IN8bio
Manufactured products of IN8bio, Inc.

A conservative investor assesses the financial stability of IN8bio, Inc. (INAB) by analyzing liabilities maturing within one year. This amount of short-term debt reflects the liquidity risk between reporting periods, which is critical for a biotech company funding costly Phase 1/2 clinical trials for glioblastoma therapy. The stability of this metric confirms the business's ability to sustain clinical development without emergency capital raises.

Main competitors

TG Therapeutics - Company Short-Term Debts|Arcellx Inc (ACLX) - Company Current Liabilities|IRON: Company Short-Term Debts|Short-Term Debt Syndax Corp (SNDX)|Company Short-Term Debt Kura Oncology, Inc.|ADCT: Company Short-Term Loans and Borrowings|Company Current Liabilities FHTX (Foghorn Therapeutics)|VOR (Vor Biopharma, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debts NKTX (Nkarta)|Coeptis Therapeutics Inc. - Company Short-Term Debt|ATNM - Company Short-Term Debt|ESLA: Company Short-Term Debt|casipharmaceuticals.com (CASI) - Company Short-Term Debt|Short-Term Debt Marker Therapeutics, Inc. (MRKR)|Company Short-Term Debt Eterna Therapeutics, Inc.|Short-Term Debt GT Biopharma Corporation GTBP|Company Short-Term Debts APTO|biopathholdings.com - Company Short-Term Indebtedness|Company Short-Term Debts MEIP (MEI Pharma)|Short-Term Debt Volume Vincerx Pharma Inc. (VINC)